Interleukin-6 targeting therapy in familial mediterranean fever

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.77, 2013, Pages

  Fujikawa, K ^a   Migita, Kiyoshi ^b   Tsukada, T ^a   Umeda, M ^c   Nonaka, F ^d   Kawakami, A ^c   Eguchi, K ^d  

^a Isahaya Health Insurance General Hospital   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^c NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^d Sasebo General Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; INTERLEUKIN 6; METHOTREXATE; PREDNISOLONE; TOCILIZUMAB;

ADULT; ADULT ONSET STILL DISEASE; CASE REPORT; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG RESPONSE; ERYTHEMA; FAMILIAL MEDITERRANEAN FEVER; FEMALE; GENE; GENE MUTATION; HUMAN; JAPANESE; LABORATORY TEST; LETTER; MEFV GENE; POLYARTHRITIS; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL, HUMANIZED; CYTOSKELETAL PROTEINS; DNA MUTATIONAL ANALYSIS; FAMILIAL MEDITERRANEAN FEVER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MOLECULAR TARGETED THERAPY; MUTATION; PHENOTYPE; RECEPTORS, INTERLEUKIN-6; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84884935434     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Letter

References (14)

1. El-SHANTI H, MAJEED HA, El-KHATEEB M: Familial mediterranean fever in Arabs. Lancet 2006; 367: 1016-24.
2. BEN-ZVI I, LIVNEH A: Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nat Rev Rheumatol 2011; 7: 105-12.
3. SORIANO A, VERECCHIA E, AFELTRA A, LANDOLFI R, MANNA R: IL-1β Biological Treatment of Familial Mediterranean Fever. Clin Rev Allergy Immunol 2013 Jan 16.
4. YAMAGUCHI M, OHTA A, TSUNEMATSU T et al.: Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992; 19: 424-30.
5. KORKMAZ C, OZDOGAN H, KASAPÇOPUR O, YAZICI H: Acute phase response in familial Mediterranean fever. Ann Rheum Dis 2002; 61: 79-81.
6. BERKUN Y, EISENSTEIN E, BEN-CHETRIT E: FMF - clinical features, new treatments and the role of genetic modifiers: a critical digest of the 2010-2012 literature. Clin Exp Rheumatol 2012; 30 (Suppl. 72): S90-5.
7. VAITLA PM, RADFORD PM, TIGHE PJ et al.: Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum 2011; 63: 1151-5.
8. BAGCI S, TOY B, TUZUN A et al.: Continuity of cytokine activation in patients with familial Mediterranean fever. Clin Rheumatol 2004; 23: 333-7.
9. SANDBORG C, MELLINS ED: A new era in the treatment of systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367: 2439-40.
10. SNEGIREVA LS, KOSTIK MM, CAROLI F, CECCHERINI I, GATTORNO M, CHASNYK VG: Failure of tocilizumab treatment in a CINCA patient: clinical and pathogenic implications. Rheumatology 2013 Mar 12. [Epub ahead of print]
11. CHAE JJ, AKSENTIJEVICH I, KASTNER DL: Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. Br J Haematol 2009; 146: 467-78.
12. CHAE JJ, WOOD G, RICHARD K et al.: The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment. Blood 2008; 112: 1794-803.
13. OZTURK MA, KANBAY M, KASAPOGLU B et al.: Therapeutic approach to familial Mediterranean fever: a review update. Clin Exp Rheumatol 2011; 29 (Suppl. 67): S77-86.
14. OKUDA Y, TAKASUGI K: Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 2006; 54: 2997-3000.